Claims for Patent: 6,415,797

Summary for Patent: 6,415,797

Title:	Treatment of human herpesviruses using hyperthermia
Abstract:	The invention provides a method of treating a patient infected with a human herpesvirus comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce or eliminate the patient\'s viral load of the human herpesvirus.
Inventor(s):	Groth; Karl Emil (St. Paul, MN), Kelly; Theodore Charles (Minnetonka, MN), Westerbeck; Todd L. (St. Paul, MN), Blick; Gary (Stamford, CT)
Assignee:	First Circle Medical, Inc. (Minneapolis, MN)
Application Number:	09/611,434
Patent Claims:	1. A method for treating a patient infected with a human herpesvirus comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce the patient's viral load of the human herpesvirus by 30 percent or more one month after the core temperature has been raised and returned to normal said at least one time, and wherein the patient's viral load of the human herpesvirus is determined at least once after the core temperature has been raised and returned to normal said at least one time. 2. The method of claim 1, wherein the core temperature of the patient is raised and returned to normal one time. 3. The method of claim 1, wherein the core temperature of the patient is raised and returned to normal two or more times. 4. The method of claim 1, wherein the core temperature is raised by circulating the patient's blood from the patient, through an extracorporeal blood flow circuit, and back to the patient, wherein the blood returned to the patient has been heated within the blood flow circuit to an elevated temperature range. 5. The method of claim 1, wherein the core temperature is raised to a temperature range of from 38 to 44.degree. C. 6. The method of claim 5, wherein the core temperature is raised for a period of from 2 minutes to sixteen hours. 7. The method of claim 5, wherein the core temperature is raised for a period of from one-half to three hours. 8. The method of claim 1, wherein the patient's viral load of the human herpesvirus is determined at least once before the core temperature has been raised said at least one time. 9. The method of claim 1, wherein the patient's viral load of the human herpesvirus is reduced by 50 percent or more one month after the core temperature has been raised and returned to normal said-at least one time. 10. The method of claim 1, wherein the patient's viral load of the human herpesvirus is reduced by 75 percent or more one month after the core temperature has been raised and returned to normal said at least one time. 11. The method of claim 1, wherein the patient's viral load of the human herpesvirus is reduced by 90 percent or more one month after the core temperature has been raised and returned to normal said at least one time. 12. The method of claim 1, wherein the patient's viral load of the human herpesvirus is reduced by 95 percent or more one month after the core temperature has been raised and returned to normal said at least one time. 13. The method of claim 1, wherein the patient's viral load of the human herpesvirus is reduced to less than the sensitivity level of a branched DNA signal amplification test one month after the core temperature has been raised and returned to normal said at least one time. 14. The method of claim 1, wherein the patient's viral load of the human herpesvirus is reduced to less than the sensitivity level of a reverse transcriptase-polymerase chain reaction test one month after the core temperature has been raised and returned to normal said at least one time. 15. The method of claim 1, further comprising treating the patient with a pharmaceutical indicated for the human herpesvirus. 16. The method of claim 15, wherein the pharmaceutical is administered before raising the core temperature of the patient said at least one time. 17. The method of claim 15, wherein the pharmaceutical is administered while the core temperature of the patient is raised. 18. The method of claim 15, wherein the pharmaceutical is administered after the core temperature of the patient has been raised and returned to normal said at least one time. 19. The method of claim 15, wherein the pharmaceutical is selected from interferons, protease inhibitors, cytokines, chemotherapeutic agents, or combinations thereof. 20. The method of claim 15, wherein the pharmaceutical is selected from ribavirin, lamivudine, interferon alfacon-1, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin alpha-1, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin-12, histamine dihydrochloride, thymalfasin, zidovudine, didanosine, zalcitabine, stavudine, abacavar, nevirapine, delaviridine, efavirenz, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, doxorubicin, aciclovir, cidofovir, famciclovir, foscarnet, ganciclovir, idoxuridine, trifluorothymidine, valaciclovir, vidarabine, or combinations thereof. 21. The method of claim 15, wherein the pharmaceutical is selected from an interferon, ribavirin, lamivudine, or doxorubicin. 22. The method of claim 15, wherein the pharmaceutical is an alpha interferon. 23. The method of claim 15, wherein the pharmaceutical is doxorubicin. 24. The method of claim 15, wherein the pharmaceutical is liposomal doxorubicin. 25. The method of claim 1, wherein the patient has an acute human herpesvirus infection. 26. The method of claim 1, wherein the patient has a latent human herpesvirus infection. 27. The method of claim 1, wherein the patient is co-infected with a pathogen. 28. The method of claim 27, wherein the pathogen is a virus. 29. The method of claim 27, wherein the pathogen is a spirochete or bacterium. 30. The method of claim 29, wherein the pathogen is a spirochete selected from the genus treponema, borrelia, or leptospira. 31. The method of claim 29, wherein the pathogen is a spirochete selected from Treponema pallidum, Treponema pertenue, Treponema carateum, Treponema pallidum endemicum, Borrelia burgdorferi, Borrelia hermsii, or Leptospira interrogans. 32. The method of claim 27, wherein the pathogen is a heat labile virus. 33. The method of claim 32, wherein the heat labile virus is selected from hepadnaviruses, togaviruses, flaviviruses, coronaviruses, rhabdoviruses, filoviruses, paramyxoviruses, othomyxoviruses, bunyaviruses, arenaviruses, or retroviruses. 34. The method of claim 32, wherein the heat labile virus is selected from HIV, hepatitis B virus, or hepatitis C virus. 35. The method of claim 1, wherein the human herpesvirus is selected from human herpes virus-8, Epstein-Barr virus, human cytomegalovirus, varicella-zoster virus, herpes simplex virus-1, herpes simplex virus-2, human herpes virus-6, or human herpes virus-7. 36. The method of claim 1, wherein the human herpesvirus is human herpes virus-8. 37. The method of claim 1, wherein the human herpesvirus is Epstein-Barr virus. 38. The method of claim 1, wherein the human herpesvirus is human cytomegalovirus. 39. The method of claim 1, wherein the human herpesvirus is varicella-zoster virus. 40. The method of claim 1, wherein the human herpesvirus is herpes simplex virus-1. 41. The method of claim 1, wherein the human herpesvirus is herpes simplex virus-2. 42. The method of claim 1, wherein the human herpesvirus is human herpes virus-6. 43. The method of claim 1, wherein the human herpesvirus is human herpes virus-7. 44. The method of claim 1, wherein the herpesvirus is HHV-8, the patient has been receiving doxorubicin, and the patient still has progressive Kaposi's sarcoma prior to the treating. 45. A method for treating a patient infected with a human herpesvirus comprising raising the core temperature of the patient and then returning the core temperature of the patient to normal at least one time, wherein the core temperature is raised to a temperature range and a duration sufficient to reduce the patient's viral load of the human herpesvirus by 30 percent or more three months after the core temperature has been raised and returned to normal said at least one time, and wherein the patient's viral load of the human herpesvirus is determined at least once after the core temperature has been raised and returned to normal said at least one time. 46. The method of claim 45, wherein the core temperature of the patient is raised and returned to normal one time. 47. The method of claim 45, wherein the core temperature of the patient is raised and returned to normal two or more times. 48. The method of claim 45, wherein the core temperature is raised by circulating the patient's blood from the patient, through an extracorporeal blood flow circuit, and back to the patient, wherein the blood returned to the patient has been heated within the blood flow circuit to an elevated temperature range. 49. The method of claim 45, wherein the core temperature is raised to a temperature range of from 38 to 44.degree. C. 50. The method of claim 49, wherein the core temperature is raised for a period of from 2 minutes to sixteen hours. 51. The method of claim 49, wherein the core temperature is raised for a period of from one-half to three hours. 52. The method of claim 45, wherein the patient's viral load of the human herpesvirus is determined at least once before the core temperature has been raised said at least one time. 53. The method of claim 45, wherein the patient's viral load of the human herpesvirus is reduced by 50 percent or more three months after the core temperature has been raised and returned to normal said at least one time. 54. The method of claim 45, wherein the patient's viral load of the human herpesvirus is reduced by 75 percent or more three months after the core temperature has been raised and returned to normal said at least one time. 55. The method of claim 45, wherein the patient's viral load of the human herpesvirus is reduced by 90 percent or more three months after the core temperature has been raised and returned to normal said at least one time. 56. The method of claim 45, wherein the patient's viral load of the human herpesvirus is reduced by 95 percent or more three months after the core temperature has been raised and returned to normal said at least one time. 57. The method of claim 45, wherein the patient's viral load of the human herpesvirus is reduced to less than the sensitivity level of a branched DNA signal amplification test three months after the core temperature has been raised and returned to normal said at least one time. 58. The method of claim 45, wherein the patient's viral load of the human herpesvirus is reduced to less than the sensitivity level of a reverse transcriptase-polymerase chain reaction test three months after the core temperature has been raised and returned to normal said at least one time. 59. The method of claim 45, further comprising treating the patient with a pharmaceutical indicated for the human herpesvirus. 60. The method of claim 59, wherein the pharmaceutical is administered before raising the core temperature of the patient said at least one time. 61. The method of claim 59, wherein the pharmaceutical is administered while the core temperature of the patient is raised. 62. The method of claim 59, wherein the pharmaceutical is administered after the core temperature of the patient has been raised and returned to normal said at least one time. 63. The method of claim 59, wherein the pharmaceutical is selected from interferons, protease inhibitors, cytokines, chemotherapeutic agents, or combinations thereof. 64. The method of claim 59, wherein the pharmaceutical is selected from ribavirin, lamivudine, interferon alfacon-1, interferon alfa-2a, interferon alfa-2b, interferon-alfa-n1, thymosin alpha-1, interleukin-2, interferon alpha-n3, ketoprofen, interferon beta-1a, interferon gamma-1b, interleukin- 12, histamine dihydrochloride, thymalfasin, zidovudine, didanosine, zalcitabine, stavudine, abacavar, nevirapine, delaviridine, efavirenz, ritonavir, indinavir, nelfinavir, saquinavir, amprenavir, doxorubicim, aciclovir, cidofovir, famciclovir, foscamet, ganciclovir, idoxuridine, trifluorothymidine, valaciclovir, vidarabine, or combinations thereof. 65. The method of claim 59, wherein the pharmaceutical is selected from an interferon, ribavirin, lamivudine, or doxorubicin. 66. The method of claim 59, wherein the pharmaceutical is an alpha interferon. 67. The method of claim 59, wherein the pharmaceutical is doxorubicin. 68. The method of claim 59, wherein the pharmaceutical is liposomal doxorubicin. 69. The method of claim 45, wherein the patient has an acute human herpesvirus infection. 70. The method of claim 45, wherein the patient has a latent human herpesvirus infection. 71. The method of claim 45, wherein the patient is co-infected with a pathogen. 72. The method of claim 71, wherein the pathogen is a virus. 73. The method of claim 71, wherein the pathogen is a spirochete or bacterium. 74. The method of claim 73, wherein the pathogen is a spirochete selected from the genus treponema, borrelia, or leptospira. 75. The method of claim 73, wherein the pathogen is a spirochete selected from Treponema pallidum, Treponema pertenue, Treponema carateum, Treponema pallidum endemicum, Borrelia burgdorferi, Borrelia hermsii, or Leptospira interrogans. 76. The method of claim 71, wherein the pathogen is a heat labile virus. 77. The method of claim 76, wherein the heat labile virus is selected from hepadnaviruses, togaviruses, flaviviruses, coronaviruses, rhabdoviruses, filoviruses, paramyxoviruses, othomyxoviruses, bunyaviruses, arenaviruses, or retroviruses. 78. The method of claim 76, wherein the heat labile virus is selected from HIV, hepatitis B virus, or hepatitis C virus. 79. The method of claim 45, wherein the human herpesvirus is selected from human herpes virus-8, Epstein-Barr virus, human cytomegalovirus, varicella-zoster virus, herpes simplex virus-1, herpes simplex virus-2, human herpes virus-6, or human herpes virus-7. 80. The method of claim 45, wherein the human herpesvirus is human herpes virus-8. 81. The method of claim 45, wherein the human herpesvirus is Epstein-Barr virus. 82. The method of claim 45, wherein the human herpesvirus is human cytomegalovirus. 83. The method of claim 45, wherein the human herpesvirus is varicella-zoster virus. 84. The method of claim 45, wherein the human herpesvirus is herpes simplex virus-1. 85. The method of claim 45, wherein the human herpesvirus is herpes simplex virus-2. 86. The method of claim 45, wherein the human herpesvirus is human herpes virus-6. 87. The method of claim 45, wherein the human herpesvirus is human herpes virus-7. 88. The method of claim 45, wherein the herpesvirus is HHV-8, the patient has been receiving doxorubicin, and the patient still has progressive Kaposi's sarcoma prior to the treating.

Details for Patent 6,415,797

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2039-02-26
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2039-02-26
Biogen Inc.	AVONEX	interferon beta-1a	For Injection	103628	05/17/1996		2039-02-26